Palisade Bio PALI
NASDAQ PALI
$1.35 -0.10 (-6.90%)
At close: Sep 30, 2026 · 4:00 PM EDT

Palisade Bio (PALI) Current Deferred Revenue (2011)

Updated

Palisade Bio (PALI) recorded Current Deferred Revenue of $52,833 in Q3 2011.

Analysis

Palisade Bio (PALI) Current Deferred Revenue (2011) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 Palisade Bio 234.35 Mn -162.09 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2011 52,833.00
API Access

Palisade Bio Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=PALI&period=max&api_key=YOUR_API_KEY